News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Invitrogen Corporation (IVGN), Clontech (BDX) Reach Settlement in Patent Litigation



5/30/2007 3:08:09 AM

CARLSBAD, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN) and Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., have jointly announced a confidential settlement of their patent litigation, following a jury decision last week in federal district court in Greenbelt, Maryland. As part of the settlement, Clontech has agreed that Invitrogen Patent Nos. 5,244,797, 5,668,005, 6,063,608, and 5,405,776 on RNase H minus reverse transcriptase (RT) are valid and enforceable. Clontech has discontinued sales of its RNase H minus RT products, including its PowerScript products, for the life of the patents. The parties did not disclose other details of their agreement.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES